Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 combined with chemotherapy with or without bevacizumab for recurrent or metastatic cervical cancer after prior immunotherapy
ChiCTR2600134691Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 in Cervical Cancer (CC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Objective response rate. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2600134691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134691.